Replimune Group Inc
Replimune Group Inc (REPL) Option Chain
As of September 18, 2026, Replimune Group Inc is trading at $13.07, a +1.56% change from the previous close. The nearest expiration is Sep 25, 2026. Implied volatility is 101.3%. IV Rank is 11%.
Read more
Tracking the REPL option chain helps you see every strike and expiry on Replimune Group Inc in one view, so you can quickly identify the contracts that fit your thesis and your risk. Replimune Group Inc's option chain lays out bids, asks, volume, open interest, and Greeks across calls and puts, giving you the full map of REPL options activity at a glance. Use our scanner to monitor the REPL option chain in real time and filter for the REPL options trades that actually meet your criteria.
An option chain is the complete listing of all available option contracts on an underlying, organized by expiration date and strike price. For REPL stock options, the chain shows side-by-side call and put data, making it easy to compare premiums, assess liquidity, and spot pricing dislocations. Reading the REPL option chain effectively means looking beyond the last price — implied volatility by strike, volume-to-open-interest ratios, and bid-ask spreads all tell you where REPL stock options are being actively traded and where they are not.
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells.
Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Credit spreads, long calls, iron condors, calendar trades — every strategy starts with the same raw material: a clean, complete option chain. Our scanner pulls Replimune Group Inc's full chain across every expiry, highlights the most liquid strikes, and lets you screen REPL options by the metrics that matter, from IV skew to volume surges. Stop scrolling through endless rows of REPL stock options — let the full option chain come to you, pre-filtered and ready to trade.
Stock Statistics
- IndustryBiotechnology
- SectorHealthcare
- IV percentile55.56% Neutral
- Market cap (M$)1,231
- 52 weeks high-19.96%
- 52 weeks low771.33%
- Analyst recommendationStrong Buy
1.00 - Target price$19.43
48.66% above the current stock price - Dividend—
- Payout ratio—
- Earnings date2026-11-05
- P/E—
- Future P/E—
- EPS (ttm)-3.28
- EPS growth next 5 years40.56%
As of September 18, 2026
| CALLs | PUTs | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prob. OTM % | Open Interest | Volume | Extrinsic Value | Intrinsic Value | Bid | Ask | Strike | Moneyness % | Bid | Ask | Intrinsic Value | Extrinsic Value | Volume | Open Interest | Prob. OTM % |
| 27.90 | 0 | 0 | 0.15 | 1.07 | 0.55 | 1.90 | 12.00 | -8.19 | — | 0.60 | 0.00 | 0.60 | 0 | 16 | 72.10 |
| 39.10 | 8 | 0 | 0.33 | 0.57 | 0.20 | 1.60 | 12.50 | -4.36 | — | 0.70 | 0.00 | 0.70 | 0 | 11 | 60.90 |
| 50.81 | 37 | 1,540 | 0.50 | 0.07 | 0.05 | 1.10 | 13.00 | -0.54 | 0.35 | 1.15 | 0.00 | 0.75 | 0 | 41 | 49.19 |
| 62.02 | 8 | 0 | 0.95 | 0.00 | — | 0.95 | 13.50 | +3.29 | 0.25 | 1.35 | 0.43 | 0.37 | 0 | 2 | 37.98 |
| 71.95 | 29 | 1 | 0.25 | 0.00 | — | 0.25 | 14.00 | +7.12 | 0.50 | 4.70 | 0.93 | 1.67 | 1 | 25 | 28.05 |
As of September 18, 2026
Scan the full option chain in one place
Browse the full REPL option chain across every strike and expiration, filter by IV, volume, and open interest, and evaluate your trade without switching tools.
Start your 14-day free trial→